Boehringer Ingelheim

Pharma's social media strategies are growing up—and working better, too, report finds
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Flag link:
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Flag link:
Boehringer ends Alzheimer's research for PDE9 blocker
Boehringer ends Alzheimer's research for PDE9 blocker
Biopharma Dive
Boehringer Ingelheim
Alzheimer's disease
PDE9 blockers
BI 409306
Flag link:
Boehringer strikes Jardiance outcomes deal with Prime PBM
Boehringer strikes Jardiance outcomes deal with Prime PBM
Biopharma Dive
Boehringer Ingelheim
Jardiance
PBMs
diabetes
Prime Therapeutics
outcomes-based contracts
Flag link:
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Drug Delivery Business News
Boehringer Ingelheim
PBMs
outcomes-based contracts
diabetes
Jardiance
Prime Therapeutics
Flag link:
Boehringer, hot on deals, adds another with Adimab collaboration
Boehringer, hot on deals, adds another with Adimab collaboration
Biopharma Dive
Boehringer Ingelheim
Adimab
drug discovery
Flag link:
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Biopharma Dive
Boehringer Ingelheim
BeiGene
tislelizumab
anti-PD-L1
drug manufacturing
Flag link:
All in: Boehringer Ingelheim more than doubles its venture fund to €250M
All in: Boehringer Ingelheim more than doubles its venture fund to €250M
Endpoints
venture capital
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim inks CNS deal with Autifony
Boehringer Ingelheim inks CNS deal with Autifony
BioPharma Dive
Boehringer Ingelheim
Autifony
CNS
Flag link:
Boehringer Ingelheim loses CFO due to disagreement on group’s strategy
Boehringer Ingelheim loses CFO due to disagreement on group’s strategy
GoinPharma
Boehringer Ingelheim
Flag link:
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
Fierce Pharma
JNJ
Eli Lilly
AstraZeneca
Boehringer Ingelheim
diabetes
Invokana
Farxiga
Jardiance
Flag link:
Boehringer Ingelheim denies rumors on acquisition of Korea’s CJ Healthcare ($896m)
Boehringer Ingelheim denies rumors on acquisition of Korea’s CJ Healthcare ($896m)
GoinPharma
Boehringer Ingelheim
Korea
CJ Healthcare
M&A
Flag link:
Boehringer wins EU approval for Humira biosimilar
Boehringer wins EU approval for Humira biosimilar
BioPharma Dive
Boehringer Ingelheim
Europe
Humira
biosimilars
Cyltezo
AbbVie
Flag link:
GlaxoSmithKline's Anoro tops Boehringer's Stiolto in head-to-head COPD tilt
GlaxoSmithKline's Anoro tops Boehringer's Stiolto in head-to-head COPD tilt
Fierce Pharma
GSK
Anoro Ellipta
Boehringer Ingelheim
Stiolto Respimat
COPD
Flag link:
Dicerna and Boehringer partner on RNAi treatment for NASH
Dicerna and Boehringer partner on RNAi treatment for NASH
Endpoints
Dicerna
Boehringer Ingelheim
NASH
RNAi
Flag link:
Boehringer Ingelheim, Anthem partner for largest real-world COPD trial
Boehringer Ingelheim, Anthem partner for largest real-world COPD trial
Drug Delivery Business News
Boehringer Ingelheim
Anthem
COPD
Flag link:
Boehringer's new risk-prediction model will tap patients who could be good Jardiance candidates
Boehringer's new risk-prediction model will tap patients who could be good Jardiance candidates
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH
Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH
GoInPharma
Boehringer Ingelheim
Pharmaxis
NASH
clinical trials
BI 1467335
Flag link:
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
Fierce Pharma
formulary
Eli Lilly
Boehringer Ingelheim
JNJ
Invokana
diabetes
CVS Caremark
Flag link:

Pages